FELBAMATE
Clinical safety rating: caution
Animal studies have proved adverse effects but may be safe for humans
Felbamate enhances GABAergic transmission and inhibits NMDA receptor activity, likely through interaction with the glycine recognition site.
| Metabolism | Hepatic metabolism via CYP3A4 and CYP2E1; also undergoes glucuronidation and hydrolysis. |
| Excretion | Renal: approximately 90% (40-50% unchanged, remainder as metabolites including p-hydroxyfelbamate, 2-hydroxyfelbamate, and felbamate monocarbamate); fecal < 5% |
| Half-life | Terminal elimination half-life: 13-23 hours in adults (mean ~20 hours); may be prolonged to 30-40 hours in patients with hepatic impairment or those on enzyme inhibitors; clinical context: requires twice-daily dosing; steady-state reached in 4-5 days |
| Protein binding | Low (22-25%), primarily to albumin |
| Volume of Distribution | 0.7-1.0 L/kg; suggests distribution into total body water with some tissue binding |
| Bioavailability | Oral: >90% (well absorbed with minimal first-pass effect) |
| Onset of Action | Oral: 1-4 hours for peak plasma concentration; clinical effect may take several days to weeks for seizure control |
| Duration of Action | Duration of anticonvulsant effect: approximately 12-24 hours; clinical note: due to half-life, twice-daily dosing maintains therapeutic levels; longer duration may be observed with higher doses or in patients with reduced clearance |
1200-3600 mg/day orally in 3-4 divided doses; initiate at 1200 mg/day and titrate by 600-1200 mg/day every 2 weeks.
| Dosage form | SUSPENSION |
| Renal impairment | CrCl <50 mL/min: reduce dose by 25-50%; CrCl <30 mL/min: avoid use or use with extreme caution. |
| Liver impairment | Contraindicated in patients with hepatic dysfunction; no established dosing guidelines. |
| Pediatric use | For Lennox-Gastaut syndrome (children ≥2 years): 15 mg/kg/day divided 3-4 times daily; titrate to 45 mg/kg/day as tolerated. |
| Geriatric use | Start at low end of dosing range; monitor renal function and for increased sedation or confusion. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Increases levels of phenytoin and valproic acid and decreases levels of carbamazepine Can cause aplastic anemia and hepatic failure.
| Breastfeeding | Felbamate is excreted in human breast milk; the milk-to-plasma ratio is approximately 0.7-0.8. Cases of neonatal drowsiness, poor feeding, and irritability have been reported. Breastfeeding is not recommended due to potential for serious adverse effects in the infant. |
| Teratogenic Risk | Felbamate is classified as FDA Pregnancy Category C. First trimester: Data in humans are limited, but animal studies have shown teratogenic effects (e.g., increased fetal death, skeletal variations). Second and third trimesters: May cause neonatal withdrawal syndrome, respiratory depression, or sedation if used near term. Use only if potential benefit outweighs risks. |
■ FDA Black Box Warning
Felbamate is associated with aplastic anemia and liver toxicity. Use only in patients whose epilepsy is refractory to other treatments and who have a favorable risk-benefit profile.
| Common Effects | Anorexia |
| Serious Effects |
["History of aplastic anemia or liver toxicity with felbamate","Known hypersensitivity to felbamate or its components"]
| Precautions | ["Risk of aplastic anemia (monitor CBCs)","Hepatotoxicity (monitor LFTs)","May cause suicidal ideation","Blood dyscrasias","Monitor for hypersensitivity reactions"] |
| Food/Dietary | No significant food interactions reported. Take with or without food. Avoid alcohol consumption. |
Loading safety data…
| Fetal Monitoring | Monitor maternal serum felbamate levels and adjust dose to maintain therapeutic range. Assess liver function tests and blood counts due to risk of aplastic anemia and hepatotoxicity. Monitor fetal growth and development via serial ultrasound. Observe neonate for signs of withdrawal, sedation, or respiratory depression after delivery. |
| Fertility Effects | In animal studies, felbamate caused reduced fertility in rats. Human data are insufficient; however, due to its CNS effects, it may impact libido or hormonal regulation. Caution in women of childbearing potential. |
| Clinical Pearls | Felbamate is reserved for refractory epilepsy due to risk of aplastic anemia and hepatotoxicity. Monitor CBC and LFTs at baseline and periodically. It is a weak inhibitor of CYP3A4 and CYP2C19, increasing levels of phenytoin, carbamazepine epoxide, and valproate. Dose adjustment of concomitant AEDs is often needed. |
| Patient Advice | Take exactly as prescribed; do not change dose or stop without talking to your doctor. · Report immediately any signs of infection (fever, sore throat, easy bruising or bleeding), jaundice, dark urine, or abdominal pain. · May cause dizziness, drowsiness, or blurred vision. Avoid driving until you know how this drug affects you. · Avoid alcohol while taking felbamate. · Do not take any other medications or supplements without consulting your healthcare provider. · If you miss a dose, take it as soon as you remember unless it is almost time for your next dose. Do not double the dose. · Keep all appointments for blood tests to monitor for serious side effects. |